In their studies, treatment with their mAb against Nectin-4 did not reduce tumor size in lung cancer xenografts [26]; indicating that blocking Nectin-4 cell adhesion may be an important component of therapeutic efficacy for a mAb in this setting. The gene discussed is NECTIN4; the disease is lung cancer.